JLE

Hématologie

MENU

Maladie résiduelle dans les leucémies aiguës Volume 26, supplément 1, Avril 2020

  • [1] Cavé H., van der Werff ten Bosch J., Suciu S. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group. N Engl J Med. 1998;339:591-598.
  • [2] van Dongen J.J., Seriu T., Panzer-Grümayer E.R. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet Lond Engl. 1998;352:1731-1738.
  • [3] Maury S., Chevret S., Thomas X. Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study. Blood. 2015;126:1.
  • [4] Jourdan E., Boissel N., Chevret S. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121:2213-2223.